price jun
number tailwind support growth
stock rais est pt
spend time manag road renew
condenc outlook henc stock see combin
drivers/tailwind benet growth includ new busi addit
lower level investment/expens return pharmedium memphi facil
tax reform stabl fundament would also highlight compani
continu benet contract protect industri lead specialti
distribut busi acknowledg on-going risk around brand
gener price recent analysi suggest trend stabl
front also appreci rhetor washington respect drug
price middlemen time opinion bark seem
wors bite modestli rais estim increas
price target reiter buy rate share
number tailwind support earn bridg
page provid detail analysi earn bridg
support above-consensu estim key tailwind
expect benet includ pharmedium memphi facil
come back on-line begin ramp product increment accret
hd smith stem ration integr compani
distribut footprint new busi addit particular rite aid
pharmerica one addit quarter tax benet recent tax reform
share repurchas stem reduc y/i capit expenditur
increas free cash ow project expect headwind
tailwind complement continu strength base busi
weve estim roughli benet lower level
invest pleas see bodi note detail analysi
compon
takeaway ndr
follow meet manag key takeaway includ
number tailwind benet ep growth potenti
acceler capit deploy enjoy signic contract
protect recent renew drug price environ remain stabl
global commerci servic anim health busi creat
healthier overal prole compani legal issu surround
opioid unit state like take materi
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
rais estim price
reiter buy rate rais price target
increas condenc outlook modestli rais ep
estim above-consensu primarili due tailwind
discuss note share current trade ep estim
discount histor averag price target
assum share eventu trade reason discount multipl
ep estim
takeaway ndr
ep growth benet number tailwind
meet manag highlight number key factor view
compel tailwind head includ
pharmedium manag seem condent pharmedium
tailwind recal product
pharmedium memphi facil complet remov
guidanc balanc remind pharmedium
primari driver behind compani recent guidanc reduct
remedi measur taken longer initi expect
estim pharmedium roughli headwind ebit
assum phamedium memphi oper resum octob
compani abl begin recaptur lost volum estim
tailwind ep assumpt model
compani recaptur third lost oper prot
hd smith manag estim ep accret hd
smith note estim came novemb us
tax reform pass result believ actual accret
higher origin guidanc given hd smith predominantli
us tax payer estim hd smith could repres tailwind
note analysi separ interest expens
tax separ bucket benet relat
increment oper prot growth
opportun estim pharmerica togeth
repres tailwind
compani success on-board store
sinc gradual process store alreadi
contribut nancial recent quarter
said believ like addit benet
top-lin oper ecienc store
fulli run
pharmerica walgreen long-tim custom close
acquisit pharmerica decemb pharmerica contract
exist supplier end june busi
transit immedi afterward like
on-board period balanc pharmerica
busi oer increment y/i tailwind
tax reform experienc benet recent us
tax reform expect modest addit benet
remind manag previous guid tax rate
would basi point origin rang
 result tailwind base estim note
tax rate favor impact year due share-
base compens dynam believ benet
isol natur necessarili repeat degre
ration distribut center inherit hd smith
network distribut center follow acquisit believ
remain signic opportun ration acquir
network exist footprint note believ certain amount
opportun alreadi captur ep bridg
oper prot growth assumpt hd smith thu
refrain ad separ tailwind ep bridg
howev import note oper ecienc could
larger current expect thu repres sourc potenti
upsid beyond
brand inflat gener deflat manag continu
believ brand inat gener deation rel
stabl within current guidanc rang note believ
level brand price activ januari could modestli
level contempl guidanc begin
year thu depend level juli activ could repres
sourc upsid balanc year continu close
monitor brand inat data enter rst day juli
look recent publish work pharmaceut price
volum sale data pleas see
expect capit deploy augment
meet manag emphas strength abc balanc sheet
variou opportun capit deploy exist cash
balanc free cash ow guidanc believ
bring gross leverag addit substanti portion
capit expenditur seem relat project
substanti complet appreci new project alway
aris think capital-expenditure could declin sourc increment
free cash ow could ultim translat higher share repurchas
current model estim could add
ep although also note manag seem open
strateg acquisit particularli within commerci servic oer
suit opportun aris
recent renew mani long-term contract top
custom signic posit expect limit near-term potenti
custom loss margin pressur associ contract renegoti
particular note follow key deal contract
esrx kaiser also recent
renew deal sam club june diplomat pharmaci may
although length agreement announc
signic contract renew horizon april
global commerci servic anim health creat healthier
compani segment refer global commerci
servic anim health repres abc overal oper
prot includ abc world courier mwi manag believ
segment logic adjac manufactur servic landscap
would surpris see compani use busi platform
addit acquisit expect segment outpac growth core
pharmaceut distribut busi time provid benet
overal margin prole
favor tone gener deation brand inat
manag continu articul gener deation rel stabl
high singl digit rang line latest publish industri data
believ recent trend industri commentari oer hope
gener deation could drift back toward mid-singl digit rang time
manag continu pleas brand inat environ
discuss
expect opioid trial go court march
continu vigor defend issu surround opioid
unit state note rst trial expect take place ohio march
still long period time denit disciplinari action
take place addit one mani defend name
current known trial monetari ne like
assign portion overal total stock perspect think
outcom trial less meaning disciplinari action like
overlook one-tim event import issu monitor
result chang abc oper overal industri volum due tighter
ep bridg headwind tailwind
walk discuss headwind tailwind embed
earn bridg seen figur
month month modest debt pay assum
model forecast headwind earn next
year higher year year interest expens
tax expect modest benet one addit
quarter tax reform oset somewhat sizabl benet
employe stock option exercis would expect repeat
degre
pharmedium februari year announc follow
us fda inspect pharmedium outsourc facil memphi
compani voluntarili suspend product facil execut
remedi measur recal memphi respons major
pharmedium outsourc compound volum although initi compani
expect would abl return facil product end
scal year decid de-risk guidanc remov
contribut complet balanc addit compani
comment without facil shut-down would comfort
maintain oper prot growth guidanc full year set
announc hd smith acquisit midpoint reduct guidanc
would suggest pharmedium headwind compani
state expect begin recaptur lost volum ramp
back full product take time conservat assum
recaptur one third lost oper prot feel
assumpt prudent light compani expect volum ramp
take time view price invest may occur recaptur
hd smith announc acquisit hd smith novemb
hd smith one largest remain independ
wholesal view deal strateg
oer synergi form consolid logist network
pharmaceut procur nancial perspect expect
deal would slightli accret adjust ep accret
recal guidanc provid novemb pre-u tax
reform estim increment contribut hd smith roughli
tailwind adjust ep note split estim
increment deal nanc expens tax two separ item
ep bridg repres expect increment
oper prot
new busi benet new busi primarili
relat long term strateg relationship walgreen march
complet previous contempl acquisit rite aid
locat increment locat benet approxim half
addit follow decemb close walgreen kkr joint
acquisit pharmaci pharmerica pmc prime vendor agreement
switch end june expir contract taken togeth
expect contract contribut adjust ep
lash group reduc midpoint segment
oper prot guidanc midpoint primarili relat
expens associ implement fusion technolog platform
erp understand expens associ implement
run new platform begin roll eventu go away
entir ep bridg give benet half expens reduct
repurchas march share repurchas
author remain board-author program note roughli
abc capital-expenditure tie project substanti complet
end scal year primarili new dc believ lower y/i capit
expenditur combin outlook core busi growth work
capit trend provid runway higher ep
bridg assum share repurchas complet ratabl throughout
growth oper profit growth build ep
bridg object assess reason rate underli busi growth
breakdown identi headwind tailwind believ
continu grow core busi core busi
perform quit well enough oset oper prot headwind
produc pharmedium invest new dc hd smith lash group
updat model assum modest rel core
oper prot growth rate believ current trend pharmaceut
price specialti pharmaceut sale continu growth abc ancillari
line busi support assumpt
